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Background: Although it has been shown that acute beta-blocker administration may reduce the presence or
severity of myocardial perfusion defects with dipyridamole stress, little information is available about the potential
effect of chronic beta-blocker treatment on the sensitivity of dipyridamole myocardial perfusion imaging (DMPI).
Methods: As a randomized clinical trial, one hundred twenty patients (103 male and 17 female) with
angiographically confirmed CAD who were on long-term beta blocker therapy (≥3 months) enrolled in a
randomized clinical trial study. The patients were allocated into two groups: Group A (n=60) in whom the
beta-blocker agent was discontinued for 72h before DMPI and Group B (n=60) without discontinuation of
beta-blockers prior to DMPI.
Results: No significant difference was noted between the groups concerning age, sex, type of the injected
radiotracer and number of involved coronary vessels. The mean rank of total perfusion scores for whole
myocardium (irrespective of reversibility or irreversibility) in group B was not significantly different from that of
group A, (65.75 vs. 55.25, P=0.096). Regarding the only irreversible perfusion defects, the mean rank of perfusion
score in group B was higher than that of group A for whole myocardium (72 vs. 49, P=0.0001); however, no
difference was noted between two groups for only reversible perfusion defects (61.0 vs. 60.0, P=0.898). The overall
sensitivity of DMPI for the diagnosis of CAD in group A (91.7%) was not statistically different from group B (90%).
Conclusion: Beta-blocker withholding before DMPI did not generally affect the sensitivity of the test for the
diagnostic purposes in our study. Thus, beta-blocker withdrawal for just the purpose of diagnostic imaging is not
mandatory particularly when medication discontinuation may cause the patients to face increased risk of heart
events.
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Scintigraphic myocardial perfusion imaging has been estab-
lished as one of the most frequently used diagnostic tools
in noninvasive assessment of the likelihood of coronary ar-
tery disease (CAD) [1-3]. Infusion of pharmacological vaso-
dilators, including dipyridamole and adenosine or exercise
treadmill test (ETT) are the main protocols of cardiac stres-
sing in these imaging interventions, although less frequently
other methods are also applied [4-6].
When ETT is selected as the stress method, discon-
tinuation of agents affecting heart rate, most importantly
beta-blockers and calcium channel blockers are usually
advised, the underlying explanation of which is to allow
heart rate to reach the age-predicted value [7]. However,
there is some debate on the necessity of discontinuation
of these agents for those patients undergoing pharmaco-
logical stress.
Some previous studies suggest that acute beta-blocker
administration may reduce the presence and severity of
myocardial perfusion defects with dipyridamole stress
[8-17]. Nevertheless, most of such studies have been per-
formed with short-term or acute beta-blocker treatment,
some after intravenous administration, rather than after
long-term oral beta-blocker treatment so that their
methods differ from the usual clinical scenario encoun-
tered in many patients referring for dipyridamole myo-
cardial perfusion imaging (DMPI) [8-17]. Few studies
suggested that coronary flow reserve measured by means
of positron emission tomography (PET) is improved in
stenosis-dependent segments of the myocardium during
long-term beta-blocker treatment, thereby b-blockers
may decrease the contrast between ischemic and non-
ischemic myocardium during hyperemia induced by
dipyridamole [18]. However, they used metoprolol as a
selective beta-1 receptor blocker and carvedilol as a
non-selective beta blocker/alpha-1 blocker and thus this
effect may not be generalized to other nonselective beta-
blockers such as propranolol. To our knowledge, no
clinical trial has been performed so far on the basis of
DMPI with single-photon emission tomography (SPET)
with random continuation or discontinuation of long-
term beta-blocker medication, to study the effect of
discontinuing chronic beta-blockade on the sensitivity of
DMPI.
The current study was designed to evaluate the effect
of discontinuing vs. continuing beta-blocker drugs on




The study was approved by the committee on ethics of
Tehran University of Medical Sciences. All patients gave
written informed consent before entering the study.One hundred twenty patients (103 male and 17 fe-
male) with angiographically confirmed CAD (i.e. more
than 50% diameter stenosis in at least one coronary ar-
tery or major branches), who were on long-term treat-
ment (≥3 months) with therapeutic dose of a beta
blocker, enrolled in a randomized clinical trial. Patients
with a past history of asthma, second degree type 2 or
third degree atrio-ventricualr block, left ventricular ejec-
tion fraction less than 50%, previous angioplasty
and/or coronary artery bypass graft were excluded
from the study.
The patients were allocated into two groups, using
permuted block randomization method [19]: Group A
(n=60) in whom the beta-blocker agent was discontin-
ued for 72 h before DMPI (i.e. for more than 5 drug
half-lives for all beta-blockers used in the study) and
Group B (n=60) without discontinuation of beta-
blockers prior to DMPI. After randomization of patients,
the average number of stenosed arteries in group A was
2.0 and in group B was 2.2 with no significant difference
between groups (P=0.180). No patient with left main
coronary artery disease was included in each group of
the study. The similarity of the two groups related to the
age, gender, dose of beta-blockers before randomization,
severity, extent and significance of CAD is shown in
Table 1.
SPET imaging
Patients were instructed to fast for at least 4h before
stress phase imaging. Caffeine, theophylline or amino-
phylline were discontinued for 48 h before the pharma-
cological stress. For stress-phase imaging, a dose of 0.56
mg/kg dipyridamole was infused intravenously (i.v.) over
a 4 min period. Radiotracer was injected i.v., 3-5 min
after the completion of dipyridamole infusion. Post-
stress imaging was performed following the injection of
925MBq technetium-99m methoxyisobutyl isonitrile
(99mTc-MIBI) or 111MBq thallium-201 (201Tl) after di-
pyridamole infusion. Half an hour after injection of
99mTc-MIBI, the patients were encouraged to eat a fat-
rich snack to accelerate hepatobiliary excretion of the
radiotracer. Cardiac SPET acquisition was performed 0.5
h after the fatty meal or one hour after i.v. injection of
the radiopharmaceutical. For 201Tl SPET, image ac-
quisition was started 10-15 min after the radiotracer
injection.
In the case of imaging with 99mTc-MIBI, the rest phase
of the study was performed in the following day using
injection of the same dose of 99mTc-MIBI at rest, while
for 201Tl SPET myocardial perfusion imaging, it was
done in the same day using re-injection of 37MBq 201Tl.
For 99mTc-MIBI SPET, image acquisitions were done
using a rotating, dual head gamma camera (Solus,
ADAC, Milpitas, CA) equipped with a low-energy high-
Table 1 Comparison of baseline variables between group of patients with discontinued beta-blocker (Group A) and the
group on beta-blockade (Group B)
Group A N=60 Group B N=60 P Value
Age (years) 55.63±12.23 52.18±10.16 0.096 (NS)*
Gender Male 55 (91.7%) 48 (80%) 0.114 (NS)
Female 5 (8.3%) 12 (20%)
Radiotracer 201Tl 40 (66.70%) 42 (70%) 0.845 (NS)
99mTc-MIBI 20 (33.30%) 18 (30%)
Average dose of beta-blocker (mg/day) Propranolol 53.2±22.4 45.7±20.1 0.230 (NS)
Metoprolol 68.5±17.3 61.7±11.7 0.375 (NS)
Atenolol 46±10.8 50.0±6.3 0.464 (NS)
Number of involved coronaries One 20 (33.30%) 12 (37.5%) 0.256 (NS)
Two 20 (33.30%) 24 (54.5%)
Three 20 (33.50%) 24 (54.5%)
Significant LAD** stenosis 46 (81.8%) 53 (88.3%) 0.093 (NS)
*NS: Non-significant.
**LAD: left anterior descending artery.
(No significant difference was noted between the groups concerning age, sex, type of the radiotracer injected, average dose of beta-blockers being administered
orally before randomization, number of involved coronary vessels and the frequency of LAD stenosis).
Figure 1 The segmentation pattern of myocardium to define
different coronary territories. (The entire left ventricular
myocardium was divided into 20 segments according to a
predetermined 20-segment model).
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pine position during the SPET acquisition. Thirty-two
azimuth images, 60s/projection, were obtained in a 180°
circular orbit, beginning from 45° right anterior oblique
to 135° left posterior oblique with step and shoot acqui-
sition on a 128×128×16 matrix and 38.5 cm detector
mask. For 201Tl SPET, all imaging parameters were simi-
lar except for using low-energy all-purpose collimator
and 64×64×16 matrix. Filtered back-projected data was
reconstructed into short-axis, vertical long-axis and
horizontal long-axis slices.
Images were interpreted by three expert nuclear medicine
physicians blinded to the patients’ clinical data and final de-
cision was reached by consensus. For this purpose, the en-
tire left ventricular myocardium was divided into 20
segments according to a predetermined 20-segment model
(Figure 1). At first, the images were qualitatively interpreted
as positive or negative for the presence of any perfusion de-
fect in more than one segment throughout the myocar-
dium. Thereafter, visual semiquantitative analysis was
performed considering a variety of artefactual findings that
can be identified only by visual assessment. The perfusion
status in each segment was classified as normal, reversible
or irreversible defect by visual comparison of the intensity
of myocardial color-coded scintillation on the stress and
rest images. The total reversible and irreversible perfusion
scores for each patient were calculated separately based on
the number of segments with any degree of reversible or ir-
reversible perfusion defects, respectively.
Statistical analysis
Considering the angiographic results as the gold stand-
ard, the sensitivity of DMPI for the detection of CAD ineach group was calculated based on 95% confidence
interval (95%CI). The combined data from the perfusion
scores of all patients in both groups were sorted and
ranked from 1, assigned to the lowest score, to 120
intended to the highest score. The average rank in group
A was compared to group B using Mann–Whitney-U-
test. In this way, the number of times that a score from
group A precedes a score from group B and the number
of times that a score from group B precedes a score
from group A were analyzed. SPSS for Windows (Re-
lease 11.5.0) was used for statistical analysis. The signifi-
cance level was 0.05.
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No significant difference was noted between the groups
concerning age, sex, type of the radiotracer injected,
average dose of beta-blockers being administered orally
before randomization, number of involved coronary ves-
sels and the frequency of left anterior descending artery
(LAD) stenosis (Table 1).
The mean rank of total perfusion scores for whole
myocardium, irrespective of reversibility or irreversibil-
ity, in group B (65.75) was not significantly different
from that of group A (55.25, P=0.096) (Figure 2).
Regarding the only irreversible perfusion defects, the
mean rank of perfusion score in group B was substan-
tially higher than that of group A for whole myocardium
(72 vs. 49, P=0.0001), (Figure 2); however, no difference
was noted between group A and B for only reversible
perfusion defects (60.0 vs. 61.0, respectively, P=0.898).
The overall sensitivity of DMPI for the diagnosis of
CAD in group A was 91.7% (95%CI: 83.1%-98.7%) and
in group B was 90% (95%CI: 82.2%-97.8%). The differ-
ence was not statistically significant (P=0.945).
Additional analysis was performed based on the type
of beta-blockers. For this purpose, the patients in groups
A and B were divided into two subgroups. The first sub-
group included the patients who were taking selective β1
receptor antagonists (i.e. metoprolol and atenolol) and
the second subgroup was composed of those who were
on nonselective β1/β2 receptor antagonists (i.e. propran-
olol and carvedilol) before entering the study. The sensi-
tivity of DMPI for the diagnosis of CAD did not differ
between groups, A and B, even across separateFigure 2 Comparison of the mean rank of perfusion score for
total, reversible and irreversible segments between patients
discontinued beta-blocker (Group A) and those on beta-
blockade (Group B) during dipyridamole myocardial perfusion
imaging. (The mean rank of total perfusion scores for whole
myocardium, irrespective of reversibility or irreversibility, in group B
(65.75) was not significantly different from that of group A (55.25,
P=0.096). Regarding the only irreversible perfusion defects, the mean
rank of perfusion score in group B was substantially higher than that
of group A for whole myocardium (72 vs. 49, P=0.0001); however,
no difference was noted between group A and B for only reversible
perfusion defects (60.0 vs. 61.0, respectively, P=0.898)).subgroups of patients based on the type of beta-blocker,
gender and age (Table 2).
Discussion
Based on our study findings, the diagnostic sensitivity of
DMPI is not significantly affected by the chronic con-
sumption of beta-blockers. There is a common and
overlapping sub-cellular and molecular pathways of ac-
tion between dipyridamole and beta-blockers. Dipyrid-
amole increases the endogenous concentration of
adenosine, the underlying mechanism of which is inhib-
ition of adenosine deaminase (ADA) enzyme. Adenosine
in turn binds to A2 receptors and subsequently
enhances the activity of its corresponding G-proteins.
The cascade will eventually lead to increase in cellular
concentration of cAMP, an event which leads to vaso-
dilatation [20-24]. In atherosclerotic coronaries, vaso-
dilatory response is restricted leading to the shift of
blood to normal coronaries (steal phenomenon). This
event is the rationale for using dipyridamole infusion to
unveil possible myocardial ischemia [25-30]. On the
other hand, beta adrenergic receptors bind to the same
stimulatory G-proteins [31,32]. Therefore, theoretically it
can be judged that inhibitors of such receptors may de-
crease activation of the corresponding G-proteins, which
eventually lead to decreased cellular concentration of
cAMP and reduced response to dipyridamole infusion
[17,26,33]. Based on these facts, others concluded that
“much of the coronary vasodilation associated with hyp-
oxia is dependent on adrenergic activation and that ad-
enosine may only play a role in sustained hypoxic
vasodilation when adrenergic receptors are intact” [33].
Such a probable effect practically could result in reduced
sensitivity of DMPI. This unpleasant outcome was sup-
posed to be easily avoided with discontinuation of beta-
blockers before stress protocol of dipyridamole infusion.
On the other hand, dipyridamole infusion causes an in-
crease in rate-pressure product, which can be considered as
one of the main explanations for dipyridamole-induced
steal phenomenon. The masking effect of beta-blockade on
such an index has been considered as another reason for
decreased sensitivity of DMPI [34].
These hypotheses were supported with findings of
some reports, which showed decreased sensitivity of
DMPI in those patients with history of calcium channel
blocker or beta-blocker treatment [34-39], although
most of them were retrospective and suffered from lim-
itations such as low sample size, lack of gold standard,
lack of individual and separate evaluation of beta-
blocker effect rather than combined effect of multiple
anti-anginal drugs [36] and acute versus chronic beta
blockade [9]. Furthermore, controversies exist so far, as
our study and also some of the other reports demon-
strate opposite findings [14,40-42].
Table 2 Sensitivity of dipyridamole myocardial perfusion imaging (DMPI) in two groups, based on age, gender and
type of beta-blocker agent
Group A Group B P value
Age ≤45 Years (19/19) 100.0% (18/18) 100.0% 1.00
>45 Years (36/41) 87.8% (36/42) 85.7% 0.940
Gender Male (50/55) 90.9% (42/48) 87.5% 0.894
Female (5/5) 100.0% (12/12) 100.0% 1.00
Type of beta-blocker Nonselective β1/β2 antagonist (35/35) 100.0% (42/48) 87.5% 0.675
Selective β1antagonist (20/25) 80.0% (12/12) 100.0% 0.659
Propranolol (35/35) 100.0% (36/42) 85.7% 0.640
Beta-blocker Carvedilol (0/0) (6/6) 100.0% -
Atenolol (5/5) 100.0% (6/6) 100.0% 1.00
Metoprolol (15/20) 75% (6/6) 100.0% 0.667
Group A: patients with discontinued beta-blockade; Group B: patients on beta-blockade.
(The sensitivity of DMPI for the diagnosis of coronary artery disease did not differ between groups, A and B, even across separate subgroups of patients based on
the type of beta-blocker, gender and age).
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withdrawal in patients with long-term beta-blockade is
expected to result in restoring adrenergic activation and
consequently better dipyridamole effect [33], rising the
heterogeneity of regional perfusion between stress and
rest phases, leading to better detection of reversible
defects that might have been overlooked in case of on-
going beta-blocker treatment. Conversely, in our study,
enduring beta-blocker treatment in the time of DMPI
was associated with the detection of more irreversible
perfusion defects, but its effect on the extent of revers-
ible perfusion abnormalities were not established. This
means that beta-blocker treatment may induce a reduc-
tion in dipyridamole-phase perfusion similar to the re-
duction in resting perfusion in the areas of stenotic
coronary arteries. The effect of beta-blocker treatment
with metoprolol on the coronary flow rate of patients
with severe CAD was assessed in another study in which
the patients underwent dipyridamole NH3-PET imaging
while randomly on and off beta-blocker medications
[10]. In these patients, both resting and hyperemic blood
flow in either stenotic or normal myocardial segments
were decreased by beta-blocker treatment, in accordance
with the finding of the present study [10]. There are two
possible explanations for these results. Adrenergic block-
ade may blunt the adenosine effect and coronary vaso-
dilatation during ischemia due to a direct interference
with the adenosine receptor or adenosine concentration
[10], resulting in less contrast between resting and post-
dipyridamole images of the ischemic areas, possibly
causing overestimation of the fixed defects. Another
possible mechanism is that the systolic pressure tends to
be decreased by beta-blockade during dipyridamole
stress; the driving pressure might be reduced and
thereby may reduce the myocardial perfusion in stenotic
areas during dipyridamole- and rest-phase imaging [10].Thus, beta-blocker withdrawal may represent more
accurate estimation of the extent of fixed versus re-
versible defects.
On the other hand, the effect of continuing beta-
blocker treatment on the heterogeneity of regional myo-
cardial perfusion had no significant impact on the
sensitivity of the DMPI in our study. As a result, regard-
ing the acknowledged risks of discontinuation of anti-
anginal medications before any diagnostic testing,
on-medication imaging protocol may be considered
adequate to reveal the presence of underlying CAD.
Nevertheless, there are some inaccuracies in the estima-
tion of myocardial defect size caused by beta-blocker
treatment, e.g. overestimation in the size of fixed defects
in our study as well as underestimation of dipyridamole-
induced defect size in a previously reported study [43].
Therefore, for the accurate analysis of the size and
extent of fixed versus reversible myocardial defects
especially in a known case of previous insult or can-
didates for long-term risk stratification, withholding
beta-blocker treatment may be considered on a case-
by-case basis.
Study limitations
Because of ethical considerations (unnecessary exposure
to radiation, inherent risks to the stress phase of MPI-
such as myocardial infarction, arrhythmia, etc.), we were
unable to conduct a within-subject study to evaluate the
effect of beta-blocker withdrawal on the sensitivity of
DMPI in a single population of patients; however, the
two groups in our study were comparable as far as the
gender, age, type of radiotracer used for imaging and the
extent of CAD were concerned. For future studies and
to come into the conclusion that beta-blockers did not
affect the sensitivity of the test using the same popula-
tion with double measurement (one for continuation
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fied. In this approach the potential confounder effects of
baseline clinical characteristics of patients would be
omitted.
Also the study was conducted in patients treated with
four different beta-blocking agents. It would have been
ideal to assess each beta-blocker disjointedly, but since
the consumption of some kinds of beta-blockers such as
carvedilol was very uncommon in our patients, a well-
powered analysis of the data by considering each type of
drug, individually, was unfeasible.
Conclusion
No difference was noted between the sensitivity of DMPI
with or without discontinuing of either selective or nonse-
lective beta-blocking agents in our study. Thus, in view of
the fact that medication discontinuation may cause the
patients to face increased risk of heart events, discontinuing
long-term beta-blocker treatment 3 days before DMPI is
not suggested especially when only the diagnosis of CAD is
the main concern. Beta-blocker withholding before MPI
may be indicated on a case-by-case basis just in those
patients referred for the accurate estimation of the size of
fixed versus reversible defects.Competing interest
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